{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:14:22Z","timestamp":1791447262526,"version":"4.3.3"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Chronic mucocutaneous candidiasis (CMC) is characterized by recurrent or persistent infections with\n                    <jats:italic>Candida<\/jats:italic>\n                    of the skin, nails, and mucous membrane. It is a rare and severe disease resulting from autoimmune defects or immune dysregulations. Nonetheless, the diagnosis and treatment of CMC still pose significant challenges. Erroneous or delayed diagnoses remain prevalent, while the long-term utility of traditional antifungals often elicits adverse reactions and promotes the development of acquired resistance. Furthermore, disease relapse can occur during treatment with traditional antifungals. In this review, we delineate the advancements in molecular diagnostic and therapeutic approaches to CMC. Genetic and biomolecular analyses are increasingly employed as adjuncts to clinical manifestations and fungal examinations for accurate diagnosis. Simultaneously, a range of therapeutic interventions, including Janus kinase (JAK) inhibitors, hematopoietic stem cell transplantation (HSCT), cytokines therapy, novel antifungal agents, and histone deacetylase (HDAC) inhibitors, have been integrated into clinical practice. We aim to explore insights into early confirmation of CMC as well as novel therapeutic options for these patients.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2024.1343138","type":"journal-article","created":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T23:24:44Z","timestamp":1706052284000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Progress in molecular diagnosis and treatment of chronic mucocutaneous candidiasis"],"prefix":"10.3389","volume":"15","author":[{"given":"Danrui","family":"Jing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanzhao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weida","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.988766","article-title":"Single-cell RNA sequencing combined with whole exome sequencing reveals the landscape of the immune pathogenic response to chronic mucocutaneous candidiasis with STAT1 GOF mutation","volume":"13","author":"Lu","year":"2022","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2016.04.023","article-title":"Treatment options for chronic mucocutaneous candidiasis","volume":"72","author":"van de Veerdonk","year":"2016","journal-title":"J Infect"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2023.2231567","article-title":"Chronic mucocutaneous candidiasis presenting as refractory fissured tongue in a patient with IL-17RC mutation: the first reported case of Chinese ethnicity","volume":"12","author":"Xie","year":"2023","journal-title":"Emerg Microbes Infect"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-679902","article-title":"Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype","volume":"127","author":"Toubiana","year":"2016","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00308-22","article-title":"Efficacy of cochleated amphotericin B in mouse and human mucocutaneous candidiasis","volume":"66","author":"Desai","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-023-01519-2","article-title":"Successful rezafungin treatment of an azole-resistant chronic mucocutaneous candidiasis in a STAT-1 gain-of-function patient","volume":"43","author":"Melenotte","year":"2023","journal-title":"J Clin Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.06.036","article-title":"Regulation of IL-17A-producing cells in skin inflammatory disorders","volume":"142","author":"Pandiyan","year":"2022","journal-title":"J Invest Dermatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jaci.2020.12.629","article-title":"Two patients with chronic mucocutaneous candidiasis caused by TRAF3IP2 deficiency","volume":"148","author":"Shafer","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-021-01026-2","article-title":"A novel TRAF3IP2 mutation causing chronic mucocutaneous candidiasis","volume":"41","author":"Marujo","year":"2021","journal-title":"J Clin Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-022-00685-y","article-title":"Chinese pedigree of chronic mucocutaneous candidiasis due to STAT1 gain-of-function mutation: A case study and literature review","volume":"188","author":"Wang","year":"2023","journal-title":"Mycopathologia"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.760019","article-title":"Case report: A new gain-of-function mutation of STAT1 identified in a patient with chronic mucocutaneous candidiasis and rosacea-like demodicosis: an emerging association","volume":"12","author":"Martinot","year":"2021","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.682350","article-title":"Case report: disseminated talaromyces marneffei infection in a patient with chronic mucocutaneous candidiasis and a novel STAT1 gain-of-function mutation","volume":"12","author":"Chen","year":"2021","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-021-01086-4","article-title":"Genetic analysis of a cohort of 275 patients with hyper-igE syndromes and\/or chronic mucocutaneous candidiasis","volume":"41","author":"Frede","year":"2021","journal-title":"J Clin Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2016.71","article-title":"Chronic mucocutaneous candidiasis disease associated with inborn errors of IL-17 immunity","volume":"5","author":"Okada","year":"2016","journal-title":"Clin Transl Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-023-01578-5","article-title":"APECED rash as the first manifestation of APECED syndrome","volume":"43","author":"Ferr\u00e9","year":"2023","journal-title":"J Clin Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nature06096","article-title":"Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome","volume":"448","author":"Minegishi","year":"2007","journal-title":"Nature"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2016.04.006","article-title":"Common variable immunodeficiency, impaired neurological development and reduced numbers of T regulatory cells in a 10-year-old boy with a STAT1 gain-of-function mutation","volume":"586","author":"Kobbe","year":"2016","journal-title":"Gene"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2022.2090860","article-title":"AIRE gene mutation predisposing chronic mucocutaneous candidiasis and pigmented retinitis in two kids from a Chinese family","volume":"11","author":"Ma","year":"2022","journal-title":"Emerging Microbes Infections"},{"key":"B19","doi-asserted-by":"publisher","first-page":"782","DOI":"10.3390\/jof9080782","article-title":"Anticytokine autoantibodies and fungal infections","volume":"9","author":"Kappagoda","year":"2023","journal-title":"J Fungi (Basel)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20091983","article-title":"Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I","volume":"207","author":"Puel","year":"2010","journal-title":"J Exp Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1084\/jem.20091669","article-title":"Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines","volume":"207","author":"Kisand","year":"2010","journal-title":"J Exp Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1126\/science.aay5731","article-title":"Aberrant type 1 immunity drives susceptibility to mucosal fungal infections","volume":"371","author":"Break","year":"2021","journal-title":"Science"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M116.753848","article-title":"Molecular mechanism and structural basis of gain-of-function of STAT1 caused by pathogenic R274Q mutation","volume":"292","author":"Fujiki","year":"2017","journal-title":"J Biol Chem"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201445344","article-title":"Gain-of-function STAT1 mutations impair STAT3 activity in patients with chronic mucocutaneous candidiasis (CMC)","volume":"45","author":"Zheng","year":"2015","journal-title":"Eur J Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1016\/j.jid.2022.05.502","article-title":"493 Chronic mucocutaneous candidiasis due to Candida auris and non-albicans Candida species in a family with a mild TP63-associated ectodermal dysplasia","volume":"142","author":"Park","year":"2022","journal-title":"J Invest Dermatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.654406","article-title":"Clinical relevance of gain- and loss-of-function germline mutations in STAT1: A systematic review","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jaci.2017.03.049","article-title":"Hematopoietic stem cell transplantation in patients with gain-of-function signal transducer and activator of transcription 1 mutations","volume":"141","author":"Leiding","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-022-01351-0","article-title":"Three adult cases of STAT1 gain-of-function with chronic mucocutaneous candidiasis treated with JAK inhibitors","volume":"43","author":"Borgstr\u00f6m","year":"2023","journal-title":"J Clin Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10875-018-0575-y","article-title":"Hematopoietic stem cell transplantation in patients with heterozygous STAT1 gain-of-function mutation","volume":"39","author":"Kiykim","year":"2019","journal-title":"J Clin Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.05.016","article-title":"Emapalumab as bridge to hematopoietic cell transplant for STAT1 gain-of-function mutations","volume":"152","author":"Kunvarjee","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-019-00662-z","article-title":"Successful allogenic stem cell transplantation in patients with inherited CARD9 deficiency","volume":"39","author":"Queiroz-Telles","year":"2019","journal-title":"J Clin Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/j.jaci.2016.11.022","article-title":"Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation","volume":"139","author":"Weinacht","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1016\/j.jaci.2017.08.040","article-title":"Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations","volume":"141","author":"Vargas-Hern\u00e1ndez","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18326","article-title":"Utility of ruxolitinib in a patient with chronic mucocutaneous candidiasis caused by STAT1 gain-of-function mutation","volume":"36","author":"Olivier","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-019-00687-4","article-title":"Novel gain-of-function mutation in stat1 sumoylation site leads to CMC\/CID phenotype responsive to ruxolitinib","volume":"39","author":"Al Shehri","year":"2019","journal-title":"J Clin Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-020-00943-y","article-title":"Stepwise reversal of immune dysregulation due to STAT1 gain-of-function mutation following ruxolitinib bridge therapy and transplantation","volume":"41","author":"Kayaoglu","year":"2021","journal-title":"J Clin Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.jaci.2018.02.045","article-title":"Baricitinib treatment in a patient with a gain-of-function mutation in signal transducer and activator of transcription 1 (STAT1)","volume":"142","author":"Meesilpavikkai","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.07.020","article-title":"Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations","volume":"142","author":"Forbes","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2027","article-title":"ROR\u03b3t drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation","volume":"12","author":"Codarri","year":"2011","journal-title":"Nat Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2031","article-title":"The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF","volume":"12","author":"El-Behi","year":"2011","journal-title":"Nat Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(95)91599-0","article-title":"White cell enhancement in the treatment of severe candidosis","volume":"346","author":"Shahar","year":"1995","journal-title":"Lancet"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6976.2010.00232.x","article-title":"Novel strategies for the prevention and treatment of Candida infections: the potential of immunotherapy","volume":"34","author":"van de Veerdonk","year":"2010","journal-title":"FEMS Microbiol Rev"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.593289","article-title":"Chronic mucocutaneous candidiasis in early life: insights into immune mechanisms and novel targeted therapies","volume":"11","author":"Shamriz","year":"2020","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu215","article-title":"CARD9 deficiency and spontaneous central nervous system candidiasis: complete clinical remission with GM-CSF therapy","volume":"59","author":"Gavino","year":"2014","journal-title":"Clin Infect Dis"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky170","article-title":"VT-1598 inhibits the in vitro growth of mucosal Candida strains and protects against fluconazole-susceptible and -resistant oral candidiasis in IL-17 signalling-deficient mice","volume":"73","author":"Break","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13192","article-title":"HDAC inhibitors modulate innate immune responses to micro-organisms relevant to chronic mucocutaneous candidiasis","volume":"194","author":"R\u00f6sler","year":"2018","journal-title":"Clin Exp Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1343138\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T23:24:46Z","timestamp":1706052286000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1343138\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,24]]},"references-count":46,"alternative-id":["10.3389\/fimmu.2024.1343138"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1343138","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,24]]},"article-number":"1343138"}}